Contemporary treatment of APL.

abstract：:Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...

journal_title：Current hematologic malignancy reports

authors： Sirulnik LA,Stone RM

更新日期：2008-01-01 00:00:00

abstract：PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

journal_title：Current hematologic malignancy reports

authors： Patel AA,Odenike O

更新日期：2020-12-01 00:00:00

abstract：:The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...

journal_title：Current hematologic malignancy reports

authors： Zappasodi R,Wolchok JD,Merghoub T

更新日期：2019-02-01 00:00:00

abstract：PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...

journal_title：Current hematologic malignancy reports

authors： Bradley TJ,Watts JM,Swords RT

更新日期：2018-12-01 00:00:00

abstract：:Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets,...

journal_title：Current hematologic malignancy reports

authors： Leick MB,Levis MJ

更新日期：2017-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...

journal_title：Current hematologic malignancy reports

authors： Bangerter LR,Griffin JM,Langer S,Hasan B,Kim WS,Murad MH,Khera N

更新日期：2018-06-01 00:00:00

abstract：:The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...

journal_title：Current hematologic malignancy reports

authors： Hebb J,Kohrt H

更新日期：2015-12-01 00:00:00

abstract：:Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...

journal_title：Current hematologic malignancy reports

authors： Frosch ZA,Abel GA

更新日期：2016-12-01 00:00:00

abstract：PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative t...

journal_title：Current hematologic malignancy reports

authors： Hunter BD,Chen YB

更新日期：2020-02-01 00:00:00

abstract：:Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...

journal_title：Current hematologic malignancy reports

authors： Selimoglu-Buet D,Solary E

更新日期：2014-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...

journal_title：Current hematologic malignancy reports

authors： Radakovich N,Nagy M,Nazha A

更新日期：2020-06-01 00:00:00

abstract：:Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...

journal_title：Current hematologic malignancy reports

authors： Zinzani PL

更新日期：2011-12-01 00:00:00

abstract：:Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

journal_title：Current hematologic malignancy reports

authors： Karp Leaf R,Cho HJ,Avigan D

更新日期：2015-12-01 00:00:00

abstract：:Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...

journal_title：Current hematologic malignancy reports

authors： Jacobson NB,Parekh N,Kalaycio M

更新日期：2006-09-01 00:00:00

abstract：PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

journal_title：Current hematologic malignancy reports

authors： Hakki M

更新日期：2020-04-01 00:00:00

abstract：:Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...

journal_title：Current hematologic malignancy reports

authors： Portell CA,Advani AS

更新日期：2012-06-01 00:00:00

abstract：PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...

journal_title：Current hematologic malignancy reports

authors： Darrah JM,Herrera AF

更新日期：2018-10-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...

journal_title：Current hematologic malignancy reports

authors： Barosi G

更新日期：2014-12-01 00:00:00

abstract：PURPOSE OF REVIEW:This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma. RECENT FINDINGS:The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1,...

journal_title：Current hematologic malignancy reports

authors： Havard R,Stephens DM

更新日期：2018-12-01 00:00:00

abstract：:High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...

journal_title：Current hematologic malignancy reports

authors： Kumar S

更新日期：2007-05-01 00:00:00

abstract：:Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

journal_title：Current hematologic malignancy reports

authors： Buckley SA,Walter RB

更新日期：2015-06-01 00:00:00

abstract：:The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...

journal_title：Current hematologic malignancy reports

authors： Roberts DA,Steensma DP

更新日期：2015-09-01 00:00:00

abstract：:Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...

journal_title：Current hematologic malignancy reports

authors： Pieters R

更新日期：2009-07-01 00:00:00

abstract：:Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...

journal_title：Current hematologic malignancy reports

authors： Dabrowska-Iwanicka A,Walewski JA

更新日期：2014-09-01 00:00:00

abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...

journal_title：Current hematologic malignancy reports

authors： La Rosée P,Hochhaus A

更新日期：2008-04-01 00:00:00

abstract：:Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...

journal_title：Current hematologic malignancy reports

authors： Forstpointner R,Dreyling M

更新日期：2011-12-01 00:00:00

abstract：PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...

journal_title：Current hematologic malignancy reports

authors： Patel SS,Majhail NS

更新日期：2018-12-01 00:00:00

abstract：:Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

journal_title：Current hematologic malignancy reports

authors： Barber NA,Bierman PJ

更新日期：2012-09-01 00:00:00

abstract：:Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...

journal_title：Current hematologic malignancy reports

authors： Bröckelmann PJ,Engert A

更新日期：2015-09-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...

journal_title：Current hematologic malignancy reports

authors： Lekakis LJ,Cooper BW,de Lima MG

更新日期：2014-06-01 00:00:00